In the Phase 3 POLARIS-AD trial involving 1,535 patients with early Alzheimer’s disease, AR1001 did not meet the primary endpoint in the overall population, but achieved the prespecified goal in the 604-patient monotherapy group not using other Alzheimer’s disease medications.
Source:Tech Times · Read original
Leave a Reply